DK164282B - Biologisk aktive fragmenter af human antihaemofilisk faktor viii:c, anvendelse af fragmenterne og fremgangsmaade til fremstilling af dem - Google Patents

Biologisk aktive fragmenter af human antihaemofilisk faktor viii:c, anvendelse af fragmenterne og fremgangsmaade til fremstilling af dem Download PDF

Info

Publication number
DK164282B
DK164282B DK085786A DK85786A DK164282B DK 164282 B DK164282 B DK 164282B DK 085786 A DK085786 A DK 085786A DK 85786 A DK85786 A DK 85786A DK 164282 B DK164282 B DK 164282B
Authority
DK
Denmark
Prior art keywords
thr
arg
factor viii
tyr
daltons
Prior art date
Application number
DK085786A
Other languages
Danish (da)
English (en)
Other versions
DK85786A (da
DK85786D0 (da
Inventor
Lars-Olof Andersson
Nanna Forsman
Kerstin Ebba Ingrid Larsen
Annelie Birgitta Lundin
Pavlu Bohdan
Inga Helena Sandberg
Karin Margareta Sewerin
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20359353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK164282(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of DK85786D0 publication Critical patent/DK85786D0/da
Publication of DK85786A publication Critical patent/DK85786A/da
Publication of DK164282B publication Critical patent/DK164282B/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02D—FOUNDATIONS; EXCAVATIONS; EMBANKMENTS; UNDERGROUND OR UNDERWATER STRUCTURES
    • E02D31/00—Protective arrangements for foundations or foundation structures; Ground foundation measures for protecting the soil or the subsoil water, e.g. preventing or counteracting oil pollution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Structural Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Civil Engineering (AREA)
  • Paleontology (AREA)
  • Mining & Mineral Resources (AREA)
  • Hydrology & Water Resources (AREA)
  • Environmental & Geological Engineering (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK085786A 1985-03-05 1986-02-25 Biologisk aktive fragmenter af human antihaemofilisk faktor viii:c, anvendelse af fragmenterne og fremgangsmaade til fremstilling af dem DK164282B (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8501050 1985-03-05
SE8501050A SE8501050D0 (sv) 1985-03-05 1985-03-05 Biologically active fragments of human antihemophilic factor and method for preparation thereof

Publications (3)

Publication Number Publication Date
DK85786D0 DK85786D0 (da) 1986-02-25
DK85786A DK85786A (da) 1986-09-06
DK164282B true DK164282B (da) 1992-06-01

Family

ID=20359353

Family Applications (1)

Application Number Title Priority Date Filing Date
DK085786A DK164282B (da) 1985-03-05 1986-02-25 Biologisk aktive fragmenter af human antihaemofilisk faktor viii:c, anvendelse af fragmenterne og fremgangsmaade til fremstilling af dem

Country Status (10)

Country Link
US (2) US4749780A (https=)
EP (1) EP0197901B1 (https=)
JP (1) JPS61205219A (https=)
AT (1) ATE65505T1 (https=)
CA (1) CA1341497C (https=)
DE (1) DE3680368D1 (https=)
DK (1) DK164282B (https=)
HK (1) HK15293A (https=)
SE (1) SE8501050D0 (https=)
SG (1) SG1893G (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362854A (en) * 1983-03-31 1994-11-08 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides: method of making
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
EP0251843A1 (fr) * 1986-06-06 1988-01-07 Transgene S.A. Procédé de préparation de facteur VIII à partir de cellules de mammifères
FR2613379B2 (fr) * 1987-04-03 1990-04-06 Transgene Sa Procede de preparation de fragments du facteur viii a partir de cellules de mammiferes
DE3788944T2 (de) * 1986-06-24 1994-05-26 Novonordisk As Verfahren zur herstellung eines koagulationsaktiven komplexes vom faktor viii-fragment.
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
JP3263759B2 (ja) * 1992-04-06 2002-03-11 プレスマスター、トゥール、アーベー クリンプ工具
DE69329795T2 (de) * 1992-10-02 2001-07-05 Genetics Institute, Inc. Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
PT1754718E (pt) 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
EP0910581B1 (de) * 1996-06-24 2000-04-05 Max-Planck-Institut für Physiologische und Klinische Forschung Kerckhoff-Klink GmbH Verfahren zur affinitätschromatographischen aufreinigung von faktor viii
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7112438B2 (en) 1999-01-04 2006-09-26 Dyax Corp. Binding molecules for human factor VIII and factor VIII-like proteins
EP1038959A1 (en) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
EP1233064A1 (en) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modified factor VIII cDNA and its use for the production of factor VIII
US7205278B2 (en) * 2001-06-14 2007-04-17 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
EP1418810A4 (en) 2001-08-03 2006-08-02 Us Gov Health & Human Serv TREATMENT OF HEMOPHILIA ORAL
PL2235197T3 (pl) 2007-12-27 2018-01-31 Baxalta GmbH Sposoby hodowli komórek
EP2704688B1 (en) * 2011-05-05 2019-07-10 Matinas BioPharma Nanotechnologies, Inc. Cochleate compositions and methods of making and using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4495175A (en) * 1982-08-05 1985-01-22 University Of Rochester Preparation of highly purified human antihemophilic factor
NO167533C (no) * 1983-03-31 1991-11-13 Scripps Clinic Res Fremgangsmaate ved fremstilling av faktor viii koagulerende polypeptider og monoklonale antistoffer overfor disse.
DE3481109D1 (de) * 1983-05-09 1990-03-01 Novo Nordisk As Antihaemophilie-faktor-viii-konzentrat und dessen herstellungsverfahren.
DE10399011I1 (de) * 1984-01-12 2003-10-23 Chiron Corp F}r Fakton-VIIIc kodierende DNA-Sequenzen und ver wandte DNA-Konstruktionen
US4710381A (en) * 1984-05-22 1987-12-01 The Blood Center Of Southeastern Wisconsin Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US4543210A (en) * 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof

Also Published As

Publication number Publication date
ATE65505T1 (de) 1991-08-15
EP0197901A1 (en) 1986-10-15
EP0197901B1 (en) 1991-07-24
JPS61205219A (ja) 1986-09-11
HK15293A (en) 1993-03-05
JPH0547524B2 (https=) 1993-07-19
DK85786A (da) 1986-09-06
DK85786D0 (da) 1986-02-25
US4877614A (en) 1989-10-31
CA1341497C (en) 2006-02-14
DE3680368D1 (de) 1991-08-29
SG1893G (en) 1993-06-11
SE8501050D0 (sv) 1985-03-05
US4749780A (en) 1988-06-07

Similar Documents

Publication Publication Date Title
DK164282B (da) Biologisk aktive fragmenter af human antihaemofilisk faktor viii:c, anvendelse af fragmenterne og fremgangsmaade til fremstilling af dem
JP3701028B2 (ja) 高純度フォンビルブラント因子の入手方法
DK173859B1 (da) Fremgangsmåde til fremstilling af et højrenset humant faktor IX koncentrat og andre plasmaproteiner
AU622133B2 (en) Plasma and recombinant protein formulations in high ionic strength media
EP0294025B1 (en) Peptides corresponding to the Factor VIII binding domain of the von Willebrand factor
US4649132A (en) Treatment of Factor VIII inhibitors
EP0182372A2 (en) New factor VIII coagulant polypeptides
US6005077A (en) Use of von willebrand factor and pharmaceutical formulation
HU214905B (hu) Eljárás VIII. faktor izolálására
Nilsson In Memory of Erik Jorpes: von Willebrand's Disease from 1926–1983
JPH0829089B2 (ja) フアクタ−▲ｖｉｉｉ▼凝固因子ポリペプチド類
Reber et al. Three abnormal fibrinogen variants with the same amino acid substitution (γ 275 Arg→ His): Fibrinogens Bergamo II, Essen and Perugia
US5484890A (en) Antihemophilic factor stabilization
EP0201574B1 (en) A preparation for the treatment of hemophilia a inhibitor patients and a process for producing such a preparation
US4769336A (en) Treatment of factor VIII inhibitors
CN101812436B (zh) 一种尖吻蝮蛇蛇毒类凝血酶及其制备方法和应用
EP0239644A1 (en) Novel physiologically active substance having blood coagulation controlling activity
US6239101B1 (en) Thrombin binding polypeptides
Cooper et al. The cold-insoluble globulin of plasma and its relationship to factor VIII
Aiken et al. Isolation and identification of a 23,000-dalton heparin binding fragment from the amino terminus of bovine thrombospondin
Nilsson Clinical characteristics of the factor VIII protein from various factor VIII concentrates
Arrighi et al. Factor VIII: c Concentrate Virus Inactivated: Progress in Purification by Using Classic Chromatographie Methods
Osbahr Structure-activity relationships of the vasopressor activity of canine peptide-A from fibrinogen
Bouma et al. Factor VIII Related Antigen in Normal Blood Platelets and in Platelets of Patients with von Willebrand’s Disease
WO1995013301A1 (en) Cross-linked factor viii